Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q3 2019 · 10-Q
Revenue$5.28M$5.28M+9.0% vs Q3 2018 Net Income-$2.30M-$2.30MN/M vs Q3 2018 EPS Diluted-$2.37-$2.37N/M vs Q3 2018 Gross Profit$2,847,000+20.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,364,000N/M Free Cash Flowderived-$2,393,000N/M Margins · derivedGross margin53.9%+5.0 pt vs Q3 2018
Operating margin-44.5%+21.6 pt vs Q3 2018
Net margin-43.5%+22.3 pt vs Q3 2018
ended Dec 31, 2018 · filed Feb 14, 2019 · 45 d after period end